publicações selecionadas
-
artigo académico
- O que dizem as crianças e os jovens: visões sobre educação, inclusão e cuidado. Indagatio Didactica. 2021
-
artigo de conferência
-
artigo de revista
- New Ruthenium-Cyclopentadienyl Complexes Affect Colorectal Cancer Hallmarks Showing High Therapeutic Potential. Pharmaceutics. 2023
- Ruthenium(II)–cyclopentadienyl-derived complexes as new emerging anti-colorectal cancer drugs 2022
- Biotinylated Polymer-Ruthenium Conjugates: In Vitro and In Vivo Studies in a Triple-Negative Breast Cancer Model. Pharmaceutics. 2022
- Surface Water and Contamination Sources in Urban River Watersheds (Northern Portugal). Ecological Engineering & Environmental Technology. 2021
- A New Family of Iron(II)-Cyclopentadienyl Compounds Shows Strong Activity Against Colorectal and Triple Negative Breast Cancer Cells.. Molecules (Basel, Switzerland). 2020
- Ruthenium–Cyclopentadienyl Bipyridine–Biotin Based Compounds: Synthesis and Biological Effect. Inorganic Chemistry. 2019
- Novel ruthenium methylcyclopentadienyl complex bearing a bipyridine perfluorinated ligand shows strong activity towards colorectal cancer cells. European Journal of Medicinal Chemistry. 2018
-
capítulo de livro
- Water Quality Indicators in River Basins—A Portuguese Case Study (Northern Portugal). Advances in Science, Technology & Innovation (ASTI). 2022
-
documento
- Estudo da atividade cancerígena de compostos de ferro (FeCp) em linhas de cancro colorretal 2023
- New ruthenium-cyclopentadienyl agents as a new strategy to fight colorectal cancer 2021
- Ruthenium-based agents as promising metallodrugs to fight colorectal cancer 2020
- New ruthenium-based agents target actin cytoskeleton in colorectal cancer cells 2020
- New ruthenium-biotinylated anticancer agents for colorectal cancer therapy 2019
- Discovering the molecular targets of new ruthenium-based anticancer agents for colorectal cancer therapy 2019
- New ruthenium-based anticancer agents: uncovering the molecular targets towards colorectal cancer therapy 2019
- Shifting KRAS hotspot mutations inhibition paradigm in colorectal cancer
-
teses